http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Exelixis Further Reduces Indebtedness by Repaying Silicon Valley Bank Term Loan
-
Exelixis to Present at the Needham & Company Healthcare Conference on April 4
-
Exelixis (EXEL) Reports Orphan Drug Designation for Cabozantinib to Treat Hepatocellular Carcinoma
-
Exelixis' Cabozantinib Granted Orphan Drug Designation for the Treatment of Hepatocellular Carcinoma
-
Exelixis Announces Webcasts of Investor Conference Presentations in March
-
Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Exelixis Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
-
Exelixis Announces Clinical Trial Collaboration with Roche to Evaluate Cabozantinib and Atezolizumab in Locally Advanced or Metastatic Solid Tumors
-
Exelixis (EXEL), Bristol-Myers Squibb (BMY) Enter Clinical Collaboration for Late-Stage Combination Trial in First-Line Renal Cell Carcinoma
-
Exelixis and Bristol-Myers Squibb Enter Clinical Collaboration for Late-Stage Combination Trial in First-Line Renal Cell Carcinoma
-
Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refractory Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
-
Exelixis to Present at the Leerink Partners Global Healthcare Conference on February 15
-
Exelixis to Release Fourth Quarter and Full Year 2016 Financial Results on Monday, February 27, 2017
-
Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Exelixis and Takeda Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Japan
-
Update on Dispute between Exelixis and Genentech, a Member of the Roche Group
-
Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
-
Exelixis and Ipsen amend exclusive licensing agreement for the commercialization and development of cabozantinib to include Canada
-
Exelixis Announces Leadership Hires in Public Affairs and Business Development to Support Growth of Company and Pipeline
-
Exelixis to Present at the BMO Prescription for Success Healthcare Conference on December 14
-
Exelixis to Present at the Piper Jaffray 28th Annual Healthcare Conference on November 29
-
Exelixis to Present at the Stifel 2016 Healthcare Conference on November 15
-
Exelixis (EXEL) Presents New Data on Cobimetinib Combo Trials in Adv. Melanoma
-
Exelixis Announces Presentation of Cobimetinib Combination Therapy Data at the Society for Melanoma Research 2016 Congress That Support Genentech’s Planned Phase 3 Pivotal Trials
-
Exelixis Announces Third Quarter and Year to Date 2016 Financial Results and Provides Corporate Update
-
Exelixis to Release Third Quarter 2016 Financial Results on Thursday, November 3, 2016
-
Exelixis (EXEL) Announces Statistically Significant Data from Cabozantinib Phase 2 in RCC
-
Exelixis Announces Positive Results from Phase 2 CABOSUN Trial of Cabozantinib Versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma Presented at ESMO 2016
-
Exelixis (EXEL) Announces Presentation of Cobimetinib, Vemurafenib, Atezolizumab Combo Phase 1b Data in BRAF V600
-
Exelixis (EXEL) Announces Encouraging Cabozantinib Combo Phase 1 Data in Genitourinary Tumors
-
Exelixis Announces Genentech Presentation of Preliminary Phase 1b Results for the Combination of Cobimetinib, Vemurafenib and Atezolizumab at ESMO 2016 Congress
-
Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab in Advanced Genitourinary Tumors
-
Exelixis and Ipsen to Host Investor and Media Briefing to Discuss Data Presented at the ESMO 2016 Congress
-
Exelixis (EXEL) Announces Initiation of CS-3150 Phase 3 as Selective Mineralocorticoid Receptor Antagonist
-
Exelixis Elects Julie Anne Smith to Its Board of Directors
-
Exelixis Announces Collaborator Daiichi Sankyo’s Initiation of Phase 3 Clinical Development for CS-3150, a Selective Mineralocorticoid Receptor Antagonist
-
Exelixis (EXEL) Updates Timing of Key Cabozantinib Clinical Data Presentation
-
Exelixis Provides Update on Timing of Key Cabozantinib Clinical Data Presentation at the ESMO 2016 Congress
-
Exelixis (EXEL) Receives EC Approval of CABOMETYX as RCC Treatment Following VEGF-Targeted Therapy
-
European Commission Approves CABOMETYX™ (cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma Following VEGF-Targeted Therapy
-
Exelixis (EXEL) Updates on Cabozantinib Phase 3 in Adv. HCC; IDMC Says Study Should Continue Unmodified
-
Exelixis Announces Outcome from First Planned Interim Analysis of the Phase 3 CELESTIAL Trial of Cabozantinib in Patients with Advanced Hepatocellular Carcinoma
-
Exelixis to Present at the Morgan Stanley Global Healthcare Conference on September 13
-
Exelixis (EXEL) Says Data from Trials of Cabozantinib and Cobimetinib Will be Subject of 15 Presentations at ESMO
-
Exelixis-discovered Compounds To Be Featured in 15 Presentations at the ESMO 2016 Congress
-
Exelixis Announces Redemption of All Remaining 4.25% Convertible Senior Subordinated Notes Due 2019
-
Exelixis Announces Second Quarter and Year to Date 2016 Financial Results and Provides Corporate Update
-
Exelixis (EXEL) and Ipsen Announces Positive CHMP Opinion for Cabometyx to Treat Advanced RCC
-
Ipsen and its Partner Exelixis Receive Positive CHMP Opinion for Cabometyx™ (Cabozantinib) for the Treatment of Advanced RCC in Adults Following Prior VEGF-Targeted Therapy
